Andrew R. Boll
2015
In 2015, Andrew R. Boll earned a total compensation of $736.3K as Chief Financial Officer at Imprimis Pharmaceuticals, a 145% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $80,000 |
|---|---|
| Salary | $196,178 |
| Stock Awards | $449,570 |
| Other | $10,600 |
| Total | $736,348 |
Boll received $449.6K in stock awards, accounting for 61% of the total pay in 2015.
Boll also received $80K in non-equity incentive plan, $196.2K in salary and $10.6K in other compensation.
Rankings
In 2015, Andrew R. Boll's compensation ranked 9,307th out of 13,638 executives tracked by ExecPay. In other words, Boll earned more than 31.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,307 out of 13,638 | 32nd |
Division Manufacturing | 3,551 out of 5,190 | 32nd |
Major group Chemicals And Allied Products | 1,295 out of 1,854 | 30th |
Industry group Drugs | 1,055 out of 1,528 | 31st |
Industry Pharmaceutical Preparations | 824 out of 1,182 | 30th |
Source: SEC filing on April 27, 2017.
Boll's colleagues
We found two more compensation records of executives who worked with Andrew R. Boll at Imprimis Pharmaceuticals in 2015.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019